Agenus Inc AGEN

$5.97 -0.17 (-2.77%)

Valuation

Market cap
277,817,000
Revenue TTM
$114,200,000
Net income TTM
$120,000
P/E (trailing)
4.03
P/E (forward)
—
Profit margin
0.11%
Debt to equity
-0.27

Trading

Volume
711,700
Avg volume
911,632
Day's range
$5.90 – $6.26
Shares out
45,247,000
Stochastic %K
15%
Beta
1.53
Analysts
Strong Buy
Price target
$20.50

Price

Company profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also d...

Show more

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
781 674 4400
Website
https://www.agenusbio.com
Address
3 Forbes Road, Lexington, United States

Latest news

Stocktwits

ggoose18 Nov 21, 5:55 AM
$AGEN maybe there is one CEO that can blow things up better than Garo? The CAPR CEO might be in so hot water?
1 replies
Hellaofagirl Nov 20, 9:23 PM
$AGEN I actually made money today, lots of money. It pays to hedge, hopefully the blood bath continues on monday! Deep out of money puts printing cash today.
0 replies
Hellaofagirl Nov 20, 9:15 PM
$AGEN Picked up total of 6,000 shares sub $6 and actually holding over weekend.
0 replies
Stefman9 Nov 20, 8:38 PM 0 replies
roomian53 Nov 20, 8:09 PM
$AGEN https://oncodaily.com/pulse/colorectal-cancer-natera
2 replies
neversurrender2024 Nov 20, 5:59 PM
$AGEN $INKT hey looks like mz giggles is getting her brazilian wax job....inkt taking a beating ....
0 replies
2_logs_higher Nov 20, 5:40 PM
$AGEN fwiw
1 replies
Hellaofagirl Nov 20, 3:00 PM
$AGEN Going to start buying here, covered my short positions.
0 replies